Job Title Sort ascending Business Location Site Date Posted Principal Clinical Data Standards Specialist Regular, Full time Innovative Medicines India Hyderabad (Office) Jan 29, 2025 Quality Assurance ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben ...

1. Die Angaben in konstanten Wechselkursen (kWk), die Kernergebnisse und der Free Cashflow sind Nicht-IFRS-Kennzahlen. Erläuterungen der Nicht-IFRS-Kennzahlen finden sich auf Seite 47 der in ...

Associate Expert Medical Device Testing Laboratory (m/f/d) Regular, Full time Innovative Medicines Austria Schaftenau jan 31, 2025 Senior Analyst Regular, Full time Innovative Medicines India ...

V letu 2024 se je v Novartisu v Sloveniji nadaljeval intenzivni naložbeni cikel. Skupna vrednost izvedenih naložb je znašala 257 milijonov evrov, pri čemer je bil poudarek na gradnji novih objektov in ...

Job Title Sort ascending Business Location Site Date Posted Quality Control Scientist Regular, Full time Innovative Medicines USA Morris Plains Feb 01, 2025 Senior Study Start-Up Lead Regular, Full ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Job Title Sort ascending Business Location Site Date Posted Analitik (m/ž/d) / FRA Analyst (m/f/d) Temporary (Fixed Term), Full time CTS Slovenia Ljubljana Jan 31, 2025 Head International Medical ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...